January 2020 Annual Meeting Edition

January 2020 Annual Meeting Edition

Volume 6, Issue 2

This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.

Table of Contents

January 2020 Issue

Editor’s Corner: Wellness 2.0

Wednesday, January 15th, 2020
We’re all talking and thinking about wellness. You couldn’t miss the emphasis at the 2019 American Society of Hematology (ASH) Annual Meeting. There was the...

January 2020 Issue

Lenalidomide Treatment Delays Progression From Smoldering to Symptomatic Myeloma

Wednesday, January 15th, 2020
Observation is the standard approach to managing most patients with smoldering multiple myeloma (MM), but results from a phase III study suggest that early...

Early Intensification of Intrathecal Chemotherapy Reduces Risk of Relapse in Pediatric ALL

Wednesday, January 15th, 2020
Two additional doses of intrathecal therapy early during induction treatment for children with newly diagnosed acute lymphocytic leukemia (ALL) who were at increased risk...
The Society Pages

Stephen Hahn Confirmed as FDA Commissioner, Beth Shaz Becomes AABB President, and more

Wednesday, January 15th, 2020
Stephen Hahn Confirmed as FDA Commissioner The U.S. Senate voted 72−18 to confirm Stephen Hahn, MD, as the FDA’s new commissioner. President Donald Trump nominated...

Acalabrutinib Approved for CLL Under New International Collaboration

Wednesday, January 15th, 2020
The FDA granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Acalabrutinib...

Shifting From Eligibility to Optimization of Transplant in Older Adults With Hematologic Malignancies

Wednesday, January 15th, 2020
In an article published in Blood Advances, researchers from the University of Chicago reported efforts to optimize outcomes after hematopoietic cell transplantation (HCT) in...
WIB_icon

Updates From ECHELON-1: Brentuximab Vedotin Provides Durable Efficacy in Hodgkin Lymphoma

Wednesday, January 15th, 2020
Previously reported results from the phase III ECHELON-1 trial suggested that replacing bleomycin with brentuximab vedotin in the standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)...
WIB_icon

Achievement of MRD Negativity Predicts Favorable Prognosis in RUNX1-RUNX1T1+ AML

Wednesday, January 15th, 2020
In patients with acute myeloid leukemia (AML) with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1+ fusion, serial assessment of measurable residual disease (MRD) can identify people at a high risk...

Bristol-Myers Wins $752 Million From Gilead in Patent Dispute

Wednesday, January 15th, 2020
Bristol-Myers Squibb has won a $752 million lawsuit against Gilead Sciences to settle a U.S. patent dispute regarding the chimeric antigen receptor (CAR) T-cell...

FDA Approves Voxelotor for Sickle Cell Disease

Wednesday, January 15th, 2020
The FDA has approved voxelotor, a once-daily oral therapy that modulates hemoglobin affinity for oxygen by binding to hemoglobin S and stabilizing it, to...

FDA Struggles to Hire Overseas Drug Facility Inspectors

Wednesday, January 15th, 2020
From 2016 to 2018, the FDA’s overseas drug facility inspections decreased by about 10%, in part because the agency has struggled to hire new...

January 2020 Issue

Perspectives on 2019’s New Hematology Drug Approvals

Wednesday, January 15th, 2020
In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Updates on ASH Clinical Practice Guidelines in Development

Wednesday, January 15th, 2020
In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Time-Limited Acalabrutinib Combination Has “Encouraging” Response Rates in Previously Untreated Chronic Lymphocytic Leukemia

Wednesday, January 15th, 2020
Watch our interview with Benjamin Lampson, MD. Preliminary results from a trial presented at the 2019 ASH Annual Meeting suggest that time-limited frontline therapy for...

Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom...

Wednesday, January 15th, 2020
Watch our interview with Jacqueline Garcia, MD. More than one-third of patients with myelofibrosis (MF) who had not responded adequately to monotherapy with the FDA-approved...

KTE-X19: A CAR T-Cell Option for Mantle Cell Lymphoma?

Wednesday, January 15th, 2020
According to results from the ZUMA-2 trial presented at the 2019 ASH Annual Meeting, 93% of patients with relapsed/refractory mantle cell lymphoma (MCL) responded...

Early-Phase Trial Shows Mosunetuzumab Induces Durable Complete Remissions in Patients With B-Cell Non-Hodgkin...

Wednesday, January 15th, 2020
Watch our interview with Stephen J. Schuster, MD. The bispecific monoclonal antibody mosunetuzumab, which binds to CD3 and CD20, led to durable responses in patients...

Early-Phase Trial Suggests Bispecific Antibody CC-93269 Has Activity in Relapsed/Refractory Multiple Myeloma

Wednesday, January 15th, 2020
Watch our interview with Luciano J. Costa, MD, PhD. CC-93269, a bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3...

Are Clinical Trial Exclusion Criteria for Patients With AML Too Strict?

Wednesday, January 15th, 2020
Watch our interview with Abby Statler, MD, MPH. In a study presented at the 2019 ASH Annual Meeting, researchers found that certain comorbidities in patients...